ArticleDiscover oncology2026
Immune infiltration differences underlying prognostic radiomics subtypes from matched MRI and RNA sequencing in patients with lower-grade gliomas.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aims to develop an MRI-based radiomics model for predicting the prognosis of LGGs and investigating associated immune infiltration patterns. MATERIALS AND
methodsRadiomics features were extracted from preoperative T1WI contrast-enhanced MRI images of 133 LGG patients from The Cancer Genome Atlas (TCGA) cohort. A total of 851 radiomic features were analyzed for each patient. The performance of the radiomics model was evaluated by calculating the area under the receiver operating characteristic curve (AUC). Cox proportional hazards regression identified predictors of progression-free survival (PFS). Additionally, paired RNA-seq data from the same cohort were used to explore immune infiltration patterns linked to the radiomic features.
resultsThe radiomics model, constructed using 11 features, demonstrated strong predictive performance for 5-year prognosis with an AUC of 0.85 (95% CI: 0.78–0.91). Cox analysis confirmed that the radiomics score was an independent predictor of PFS. Cluster analysis revealed that patients with an immune-inflammatory phenotype exhibited higher radiomic scores and lower tumor purity, suggesting that the radiomics model correlates with altered humoral immunity.
conclusionMRI-derived radiomics scores effectively predict the prognosis of LGGs. Immune-inflammatory phenotypes are associated with higher radiomics scores, indicating more aggressive tumor characteristics and poorer prognosis compared to immune-desert phenotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.